SHIM
STOK icon

Stone House Investment Management’s Stoke Therapeutics STOK Stock Holding History

Stone House Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3K Hold
500
– – ﹤0.01% 298
2025
Q4 		$15.9K Hold
500
– – ﹤0.01% 272
2025
Q3 		$11.8K Hold
500
– – ﹤0.01% 272
2025
Q2 		$5.67K Hold
500
– – ﹤0.01% 308
2025
Q1 		$3.33K Buy
+500
New +$4.66K ﹤0.01% 354
2024
Q4 		– Sell
-500
Closed -$6.14K – 306
2024
Q3 		$6.14K Hold
500
– – ﹤0.01% 257
2024
Q2 		$6.75K Hold
500
– – ﹤0.01% 255
2024
Q1 		$6.75K Buy
+500
New +$3.03K ﹤0.01% 267

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Stone House Investment Management's STOK Position: Q1 2026 in Review

Stone House Investment Management held its Stoke Therapeutics (STOK) position steady in Q1 2026 at 500 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #298.

Stone House Investment Management first reported a position in STOK in Q1 2024 and has held it in 8 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Stone House Investment Management held 500 shares of Stoke Therapeutics worth $16.3K as of Q1 2026.
  • Stone House Investment Management left its Stoke Therapeutics share count unchanged in Q1 2026.
  • Stoke Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #298 holding.
  • Stone House Investment Management first reported a position in Stoke Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.